Madrigal Pharma stock soars 10% on profit beat, strong Rezdiffra sales

Madrigal reported third-quarter adjusted EPS of $1.83 versus analyst estimates for a loss of $0.83, while revenue rose 50% year over year to $431.3 million, beating the $405.27 million consensus. The company recorded its first profitable quarter, with net income of $55.4 million versus a $114.2 million net loss in the prior-year quarter, driven by Rezdiffra sales; year-to-date sales reached $1.1 billion and more than 55,850 patients were on treatment as of Sept. 30. Shares rose 10.17% in premarket trading. Madrigal also plans a second Phase 3 outcomes trial, expected to begin in the first half of 2027 subject to regulatory discussions.

Analysis

The quarter strengthens the commercial proof point, but the key underwriting question shifts from launch velocity to durability: patient persistence, net pricing after rebates, and the conversion of diagnosed patients into treated patients. Those details are not provided, so headline sales growth alone cannot establish a steady-state revenue run rate. The emerging operating leverage is positive, but MDGL remains highly exposed to one product and to whether later outcomes data support broader use.

Competitive effects are mixed. Obesity drugs could expand MASH detection and referral activity, enlarging the funnel, while also competing for prescriber attention and payer budget; the net effect on Rezdiffra uptake is uncertain. Other MASH pipeline entrants could pressure access or pricing over time, but the article provides no evidence of near-term displacement.

Near term, the premarket gap raises the risk that favorable execution is already reflected in the price; without valuation and forward-estimate data, we would not chase. Over 1–3 months, monitor prescription growth, access, and management commentary on persistence and net price. Over 6–18 months, commercial durability matters more than the 2027 trial catalysts. The major reversal risks are slowing patient additions, weaker-than-expected persistence or net price, and adverse regulatory or clinical developments. The contrarian point: blockbuster sales do not yet prove a durable franchise, but continued adoption could make the market’s addressable-patient estimate conservative if diagnosis and treatment rates rise.

Key Decisions for Investors

• Do not add into the immediate gap. For investors seeking exposure, consider scaling into MDGL on post-event consolidation rather than treating the EPS beat as a standalone valuation signal; no price target is justified without current valuation and forward estimates.
• Keep any MDGL position sized for single-product and clinical-outcomes risk. Reassess if prescription or treated-patient growth decelerates, or if reported revenue growth is not supported by persistence and net-price data.
• Track 1–3 month updates on payer access, treatment persistence, and net pricing as the key checks on whether commercial momentum converts into durable earnings power.
• Treat the planned Phase 3 initiation and late-2027 outcomes data as longer-dated catalysts, not near-term reasons to pay up. Revisit the thesis if regulatory discussions delay the trial or outcomes data undermine the case for broader use.